中信資源(01205.HK)盈警:預期中期股東應占綜合溢利同比減少約48%至66%
格隆匯6月25日丨中信資源(01205.HK)公吿,集團預期於截至2025年6月30日止6個月("有關期間")錄得股東應占未經審核綜合溢利約1.19億至1.84億港元,較去年同期綜合溢利約2.65億港元減少約48%至66%。
有關期間的股東應占未經審核綜合溢利預期減少主要由於以下因素所致:(i)2025年前五個月集團大宗商品的平均銷售售價,包括原油和煤,較去年同期大幅下降;及(ii)自2024年7月18日起,集團不再持有Alumina Limited任何股權,應占聯營公司的利潤大幅減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.